Why Replimune Group, Inc.’s (REPL) Stock Is Up 128.10%
As of Friday, July 31, Replimune Group, Inc.’s REPL share price has surged by 128.10%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Commentary & Analysis
Why Replimune Group, Inc.’s (REPL) Stock Is Up 93.35%
As of Friday, July 31, Replimune Group, Inc.’s REPL share price has surged by 93.35%, which has investors questioning if this is right time to sell.Omar Beirat
Why Replimune Group, Inc.’s (REPL) Stock Is Down 5.98%
As of Wednesday, July 29, Replimune Group, Inc.’s REPL share price has dipped by 5.98%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Replimune Group, Inc.’s (REPL) Stock Is Down 30.94%
As of Tuesday, July 28, Replimune Group, Inc.’s REPL share price has dipped by 30.94%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Replimune Group, Inc.’s (REPL) Stock Is Down 29.61%
As of Tuesday, July 28, Replimune Group, Inc.’s REPL share price has dipped by 29.61%, which has investors questioning if this is right time to buy.Tudor Pop
Financial Summary
| Share Statistics | REPL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $939.6 | $252.6 | 44% |
|
| Shares Out (Mil) | 95.6 | 52.3 | 61% |
|
| Institutional Ownership | 97.2% | 92.1% | 73% |
|
| Float (Mil) | 59.7 | 40.2 | 51% |
|
| Beta | 0.87 | 0.95 | 51% |
|
| Avg Daily Volume (000s) | 10,088 | 455 | 96% |
|
| Price Change (52-week) |
198.4% | 52.9% | 97% |
|
| Growth | REPL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (31.2%) | (9.9%) | 13% |
|
| EPS (5yr) | (14.1%) | 16.0% | 19 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (17.0%) | (15.6%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 3 | |
| Current EPS | ($0.545) | ($1.935) | ($1.153) | |
| Month Ago EPS | ($0.545) | ($1.935) | ($1.153) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.603) | ($2.082) | ($1.357) | |
| Year/Year Chg | (28.9%) | (42.8%) | (78.9%) | |
| Financials | REPL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($314) | ($43) | 4% |
|
| EPS (TTM) | ($3.383) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($280) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $98 | $5 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $108 | $5 | 45% |
|
| Enterprise Value (Q1) (Mil) | $785 | $180 | 39% |
|
| Valuation | REPL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.57 | 2.56 | 81% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | REPL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (71.0%) | (49.8%) | 8% |
|
| ROE | (107.9%) | (55.5%) | 9% |
|
| Liabilities to Assets | 50.0% | 30.3% | 42% |
|
| F-Score | 1 | 3 | 1% |
|
Replimune Group, Inc. did not pass any screens on 7/31/2026.
